Overview

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Status:
Recruiting
Trial end date:
2020-09-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop an auto-injector (AI) device for the BMS-986036 subcutaneous formulation that can be self-administered conveniently by participants.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb